BDSX (Biodesix, Inc. Common Stock) Stock | Pipeline, Insider Trades & Financials

Jul 22, 2026

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

Biodesix, Inc. announced it will release its second quarter financial results on August 5, 2026. The company will hold a conference call and webcast at 4:30 p.m. Eastern Time to discuss these results and provide a business update. Interested parties can register for the webcast and participate in a Q&A session.

May 11, 2026

▲ +5.2%on this news

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Biodesix, Inc. announced that it will present real-world clinical and economic data related to its Nodify Lung testing at the ATS Annual Meeting from May 15-20, 2026. The presentations aim to demonstrate the value of blood-based testing in lung cancer detection and management. CEO Scott Hutton emphasized the importance of these tests in enhancing patient care and outcomes.

May 4, 2026

Biodesix Announces First Quarter 2026 Results and Highlights Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 mil

Biodesix, Inc. reported strong financial results for the first quarter of 2026, achieving $25.6 million in revenue, a 42% increase compared to the same period in the previous year. The company also reported a gross margin of 84% and has raised its revenue guidance for the full year to a range of $108 to $114 million, reflecting a projected growth of approximately 25%. Significant growth was seen in both the Diagnostic Testing and Development Services segments, with the latter's revenue doubling year-over-year. However, Biodesix recorded a net loss of $7.8 million, highlighting ongoing financial challenges despite the positive revenue trajectory.

Apr 20, 2026

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Biodesix, Inc. announced its financial results for Q1 2026 will be released on May 4, 2026. A conference call and webcast will follow to discuss these results and provide a business update. The company emphasizes its commitment to improving clinical care through its diagnostic solutions.

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Biodesix announced the publication of the largest clinical validation study for lung nodule biomarkers, supporting the Nodify CDT test's role in early lung cancer detection. The study demonstrated high specificity and consistent performance across various clinical settings, addressing a critical need in managing lung nodules. The findings are expected to enhance clinical decision-making and patient outcomes.

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q

Biodesix, Inc. reported strong financial results for the fourth quarter and fiscal year 2025, including a 41% revenue increase to $28.8 million and an impressive gross margin of 83%. The company improved its net loss by 52%, recording its first positive Adjusted EBITDA of $0.5 million. For fiscal 2026, Biodesix anticipates revenue growth between $106 million and $112 million, showcasing optimism for continued profitability. The results reflect successful strategies in diagnostic testing and development services, strengthening Biodesix's position in the market.

Feb 24, 2026

Biodesix to Participate in Upcoming Investor Conferences

Biodesix, Inc. (Nasdaq: BDSX) has announced its participation in two upcoming investor conferences, including TD Cowen's 46th Annual Health Care Conference and Barclays 28th Annual Global Healthcare Conference. The management team will engage in fireside chats, which will be available for live streaming and replay on the company's website. This initiative highlights Biodesix's commitment to enhancing investor relations and promoting its diagnostic solutions.

Feb 24, 2026

Biodesix to Participate in Upcoming March 2026 Investor Conferences

Biodesix, Inc. has announced its participation in two upcoming investor conferences in March 2026. The management team will engage in fireside chats at the TD Cowen's 46th Annual Health Care Conference in Boston and the Barclays 28th Annual Global Healthcare Conference in Miami. These events aim to enhance investor relations and showcase the company's diagnostic solutions.

Feb 12, 2026

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Biodesix, Inc. has announced the release of its financial results for Q4 and the full year of 2025, scheduled for February 26, 2026. The company will host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Interested parties can register for the webcast and participate in a Q&A session.

Jan 12, 2026

▲ +48%on this news· ran to +81% by day 1

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24

Biodesix, Inc. reported preliminary financial results for the fourth quarter and full year of 2025, showing significant revenue growth. Estimated Q4 revenue reached $28.8 million, a 41% increase, while full-year revenue is estimated at $88.5 million, reflecting a 24% rise. The company also affirmed expectations of positive Adjusted EBITDA for Q4 2025. Additionally, growth in Lung Diagnostics revenue was driven by an increase in test volumes and enhancements in reimbursement.

Biodesix Announces Third Quarter 2025 Results and Highlights Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY202

Biodesix, Inc. reported its financial results for the third quarter of 2025, revealing a revenue of $21.8 million, a 20% increase from the previous year. The company also reported an impressive gross profit margin of 81%, marking a 400-basis point improvement. Biodesix raised its full-year revenue guidance for 2025 to between $84 million and $86 million, reflecting strong business momentum. Additionally, significant growth in its Development Services division, which saw a 97% increase in revenue, highlights successful strategic efforts in both diagnostic and service offerings.

Sep 11, 2025

▼ -20.8%on this news· ran to -37% by day 3

Biodesix Announces One-for-Twenty Reverse Stock Split Louisville, CO

Biodesix, Inc. announced a one-for-twenty reverse stock split effective September 15, 2025, which was approved by stockholders earlier this year. This split will reduce the number of outstanding shares from approximately 156 million to about 8 million without changing ownership percentages. The company will maintain its trading symbol, BDSX, on the Nasdaq Global Market, and stockholders will receive cash payments for any fractional shares resulting from the split. The company emphasizes that all adjustments will uniformly affect stockholders.

Biodesix Announces Second Quarter 2025 Results and Highlights Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating

Biodesix, Inc. reported a strong performance in Q2 2025 with a revenue increase of 12% from the prior year, totaling $20.0 million. The company achieved a gross profit margin of 80%, reflecting operational efficiencies and growth in its lung diagnostic testing and Development Services sectors. Notably, revenues in Development Services surged by 53%, signaling positive trends in business expansion. However, Biodesix also faced an increase in operating expenses and reported a net loss of $11.5 million, reinforcing the challenges associated with its growth trajectory.

May 13, 2025

Biodesix Announces First Quarter 2025 Results and Highlights Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 20

Biodesix, Inc. reported robust financial results for Q1 2025, showing a 21% increase in revenue to $18.0 million compared to the same quarter in 2024. The company achieved gross margins of 79.4%, and the net loss improved by 18%. Despite successful financial results, Biodesix has revised its 2025 revenue guidance due to delays in commercial expansion. The firm remains optimistic about achieving adjusted EBITDA positivity by the fourth quarter of 2025.

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance

Biodesix, Inc. (Nasdaq: BDSX) reported a robust performance for fiscal year 2024, achieving total revenues of $71.3 million, which represents a 45% increase from the previous year. The company's gross margins also reflected positive growth, hitting 78%, bolstered by significant increases in Lung Diagnostics and Biopharma Services revenues. While the company posted a net loss of $42.9 million, there was an improvement over prior year losses. Looking ahead, Biodesix anticipates a strong year with a revenue guidance of $92 to $95 million for fiscal year 2025.

Jan 10, 2025

▼ -14.2%on this news· ran to -25% by day 3

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited) Grew full-year revenue to an estimated $71.3 million, an increase of 45% LOUISVILLE, CO

Biodesix, Inc. (BDSX) reported preliminary financial results for 2024, indicating a substantial revenue increase of 45% to an estimated $71.3 million. The company experienced notable growth in both its Lung Diagnostics and Biopharma Services sectors. Despite these strong results, the figures are preliminary and subject to final review. CEO Scott Hutton expressed pride in the team's accomplishments and highlighted progress on operational efficiencies and partnerships, setting expectations for continued success in 2025.

Biodesix Announces Third Quarter 2024 Results and Highlights Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compare

Biodesix, Inc. announced strong Q3 2024 results, with revenue climbing 35% to $18.2 million and an improved gross profit margin of 77.0%. The company saw notable growth in lung diagnostics, achieving a 40% increase in revenue year-over-year. Despite a decrease in biopharmaceutical services revenue and rising operating expenses, the net loss improved by 6% compared to the previous year. The company reiterates its revenue guidance of $70-$72 million for 2024 and aims for adjusted EBITDA profitability in the second half of 2025.

Aug 15, 2024

Corporate Presentation Biodesix is a blood-based lung diagnostic company addressing a large unmet need with limited competition 2024 Biodesix, Inc. All rights reserved. 1 3Q24 Disclaimer This presentation and the accompa

Biodesix, Inc. presented information revealing strong growth in its lung diagnostic tests, with record revenue growth and improvements in net loss. The company is positioned to capture a significant market opportunity in lung cancer diagnostics, catering to an estimated 5 million patients with lung nodules. Additionally, Biodesix's operations have demonstrated strong margins and increased guidance for future revenue expectations, signaling a positive trajectory amid the challenges of the diagnostics industry.

Aug 7, 2024

Biodesix Announces Second Quarter 2024 Results and Highlights Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue g

Biodesix, Inc. (BDSX) reported a robust financial performance for the second quarter of 2024, showing a 51% increase in revenue year-over-year to $17.9 million. The company also improved its gross profit margin to 78.4% and raised its annual revenue guidance to $70-72 million. Additionally, Biodesix recorded improvements in net loss and Adjusted EBITDA, indicating a positive trend towards profitability. Notably, the performance is supported by significant growth in its lung diagnostic services, which are being increasingly adopted in the market.

May 8, 2024

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management First quarter 2024 Total Revenue of $14.8 million, a year-over-year increase of 64%, and 7th consecutiv

Biodesix, Inc. reported its financial results for the first quarter of 2024, achieving a revenue of $14.8 million, a significant increase of 64% compared to the same period last year. The company experienced a record gross profit margin of 79% and saw a 149% growth in its Biopharmaceutical Services division. The successful $55 million capital raise is expected to support further commercial expansion and operational improvements. CEO Scott Hutton emphasized the ongoing growth in lung diagnostic testing and the company's aim to achieve profitability.

Apr 5, 2024

▼ -7.3%on this news· ran to -19% by day 3

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement LOUISVILLE, CO

Biodesix, a company specializing in diagnostic solutions for lung disease, has announced an oversubscribed underwritten public offering of approximately 17.4 million shares of common stock at $1.15 per share. Additionally, the company is proceeding with a concurrent private placement of over 760,000 shares of non-voting convertible preferred stock. The total expected gross proceeds from both transactions is around $55 million, subject to stockholder approval. The offerings are scheduled to close around April 9, 2024, pending customary conditions.

Mar 1, 2024

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive

Biodesix, Inc. released its fourth quarter and fiscal year 2023 financial results, highlighting significant growth in Lung Diagnostic test volumes, which rose by 65% year-over-year. The company reported a gross profit margin increase to 77%, and it anticipates total revenues between $65 million to $68 million for 2024. Adjusted EBITDA improved by 55% in the fourth quarter compared to the previous year, indicating progress in its financial health. However, the company also noted a net loss of $52.1 million for the fiscal year, reflecting continuous financial challenges despite its growth achievements.

Nov 7, 2023

Biodesix Announces Third Quarter 2023 Results and Highlights Third quarter 2023 Lung Diagnostic test volume grew 60% over the comparable period in 2022 and 6% over second quarter of 2023; Third quarter 2023 gross profit

Biodesix, Inc. announced its financial results for Q3 2023, showcasing a significant 60% increase in Lung Diagnostic test volume compared to the previous year. The company reported a gross profit margin of 76%, which reflects a noteworthy improvement from 67% in Q3 2022. While the net loss decreased by 20%, it still stands at $10.9 million. Overall, Biodesix has maintained a positive trajectory in its business growth, although it adjusted its 2023 financial outlook due to changes in revenue collection assumptions.

Aug 7, 2023

Biodesix Announces Second Quarter 2023 Results and Highlights Second quarter 2023 Core Lung Diagnostic revenue of $11.4 million increased 58% over the comparable period in 2022 and 33% over the first quarter of 2023; Sec

Biodesix, Inc. reported strong financial results for the second quarter of 2023, with Core Lung Diagnostic revenue reaching $11.4 million, an increase of 58% year-over-year. The company maintained a gross profit margin of 73% and reaffirmed its full-year revenue guidance of $52 to $55 million. Additionally, Biodesix completed a successful private placement raising $27.5 million to support growth. Despite the positive metrics, the company reported a net loss of $13.4 million and a decline in BioPharma Services revenue, highlighting some areas of concern.

May 11, 2023

Biodesix Announces First Quarter 2023 Results and Highlights First quarter 2023 Core Lung Diagnostic revenue of $8.6 million increased 86% over the comparable period in 2022; Record number of Core Lung Diagnostic tests d

Biodesix, Inc. reported first quarter 2023 results showing a substantial increase in Core Lung Diagnostic revenue, which reached $8.6 million, reflecting an 86% year-over-year growth. The total revenue for the quarter was $9.1 million, a 38% increase compared to the same period last year. Despite the positive growth, the company experienced a notable decrease in revenues from BioPharma Services and COVID-19 testing. Biodesix maintains its financial outlook for 2023, forecasting total revenues between $52 million and $55 million.

Mar 6, 2023

▼ -10%on this news· ran to -24% by day 3

Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights Fourth Quarter and Fiscal Year 2022 Core Lung Diagnostic Revenue of $8.2 Million and $29.3 Million Increased 51% and 57% over the comparab

Biodesix, Inc. reported its financial results for the fourth quarter and fiscal year 2022, highlighting a 57% increase in core lung diagnostic revenue. The company anticipates total revenue between $52 million and $55 million for 2023, reflecting strong expected growth. Despite the gains in core diagnostics, Biodesix experienced a 30% decline in total revenue primarily due to a substantial drop in COVID-19 testing income. The company noted a net loss increase of 53% in the fourth quarter compared to the previous year, influenced by debt modifications.

Dec 16, 2022

Biodesix's most recent annual report on Form 10-K, filed

Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors Boulder, CO.--(BUSINESS WIRE)--December 16, 2022 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointm

Nov 16, 2022

▲ +8.5%on this news· ran to +34% by day 1

Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million $30 million initial funding $20 million in future revenue milestone-based funding Strengthens balance sheet and extends

Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million $30 million initial funding $20 million in future revenue milestone-based funding Strengthens balance sheet and extends runway with five-year interest only period BOULDER, CO,

Nov 3, 2022

Biodesix Announces Third Quarter 2022 Results and Highlights Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expand

Biodesix Announces Third Quarter 2022 Results and Highlights Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Administration and Military

Oct 11, 2022

Biodesix Announces Preliminary Revenue for Third Quarter 2022 Third quarter 2022 core lung diagnostic testing revenues growth up 96% to 103% compared to third quarter 2021 Boulder, CO

Biodesix Announces Preliminary Revenue for Third Quarter 2022 Third quarter 2022 core lung diagnostic testing revenues growth up 96% to 103% compared to third quarter 2021 Boulder, CO, October 11, 2022- Biodesix, Inc. (NASDAQ: BDSX), a leading data-driven diagnostic solutions c

Aug 4, 2022

Biodesix Announces Second Quarter 2022 Results and Highlights Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify C

Biodesix Announces Second Quarter 2022 Results and Highlights Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify CDT Lung Nodule Test; Announced strategic arrangements dur

Biodesix Announces First Quarter 2022 Results and Highlights First quarter 2022 core Lung Diagnostic revenue of $4.6 million increased 17% over the comparable period in 2021; Continued to strengthen financial position th

Biodesix Announces First Quarter 2022 Results and Highlights First quarter 2022 core Lung Diagnostic revenue of $4.6 million increased 17% over the comparable period in 2021; Continued to strengthen financial position through an additional $27.4 million in debt and equity fundi

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan Approximately $11.7 million in Common Shares Sold Under a Private Placement Third Amendment to 2021 Term Loan Provides Additional Fi

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan Approximately $11.7 million in Common Shares Sold Under a Private Placement Third Amendment to 2021 Term Loan Provides Additional Financial Flexibility for Growth BOULDER, CO, April 11, 202

Mar 14, 2022

Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 peri

Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively Full-Scale Launch of GeneStrat NGS Test

Mar 7, 2022

Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital BOULDER, CO

Biodesix Announces Common Stock Purchase Agreement for up to $50 Million with Lincoln Park Capital BOULDER, CO, March 7, 2022 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a pur

Feb 14, 2022

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (unaudited) Core lung diagnostic testing revenues grow 49% for full-year 2021 Boulder, CO

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (unaudited) Core lung diagnostic testing revenues grow 49% for full-year 2021 Boulder, CO, February 14, 2022- Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus i

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan Approximately $16.3 million in Common Shares Sold Under At-the-market Agreement Used to Offset Prepayment of Debt Second Amendment t

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan Approximately $16.3 million in Common Shares Sold Under At-the-market Agreement Used to Offset Prepayment of Debt Second Amendment to $30 Million Term Loan Provides Additional Financial Flex

Dec 8, 2021

Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors Boulder, CO.--(BUSINESS WIRE)

Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors Boulder, CO.--(BUSINESS WIRE)--December 8, 2021 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung

Nov 15, 2021

Biodesix Announces Third Quarter 2021 Results and Highlights Third Quarter 2021 Lung Diagnostic Revenue of $4.5 Million Increased 51% over Third Quarter 2020 Company launches 72-hour Next Generation Sequencing (NGS) test

Biodesix Announces Third Quarter 2021 Results and Highlights Third Quarter 2021 Lung Diagnostic Revenue of $4.5 Million Increased 51% over Third Quarter 2020 Company launches 72-hour Next Generation Sequencing (NGS) test Conference Call and Webcast Today at 9:00 a.m. ET BOULD

Sep 9, 2021

This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ( Biodesix , "we" or the Company ) for informational purposes only and not for any other purpose. Nothing contained in this pr

Third Quarter 2021 Corporate Presentation Exhibit 99.1 This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ("Biodesix", "we" or the "Company") for informational purposes only and not for any other purpose. Nothing contained in this prese

Aug 10, 2021

▲ +7.4%on this news· ran to -21% by day 1

Biodesix Announces Second Quarter 2021 Results and Highlights Second Quarter 2021 Revenue of $11.9 Million Increased 180% and Lung Diagnostic Revenue of $4.8 Million Increased 109% over Second Quarter 2020 Announcing Acc

Biodesix Announces Second Quarter 2021 Results and Highlights Second Quarter 2021 Revenue of $11.9 Million Increased 180% and Lung Diagnostic Revenue of $4.8 Million Increased 109% over Second Quarter 2020 Announcing Acceleration of the Launch of the 72-hour liquid NGS Test to

May 11, 2021

Biodesix, Inc. Condensed Balance Sheets (unaudited) (in thousands)

Biodesix Announces First Quarter 2021 Results First Quarter 2021 Record Revenue of Approximately $28.9 Million Representing 466% Growth over First Quarter 2020 Announced Plans to Launch Two New Diagnostic Tests - SARS-CoV-2 Neutralization Antibody Detection Test and Next Genera

Mar 23, 2021

Biodesix Announces Closing of New $30 Million Term Loan Increases Company's Net Liquidity Position and Reduces Near-Term Cash Interest Costs Boulder, CO

Biodesix Announces Closing of New $30 Million Term Loan Increases Company's Net Liquidity Position and Reduces Near-Term Cash Interest Costs Boulder, CO, March 23, 2021- Biodesix, Inc. (NASDAQ: BDSX; "Biodesix" or the "Company") a leading data-driven diagnostic solutions compan

Mar 16, 2021

Biodesix, Inc. Condensed Statements of Operations (unaudited) (in thousands, except per share data) Three Months Ended December 31, Years Ended

Biodesix Announces Fourth Quarter and Full Year 2020 Results Full Year 2020 Revenue Growth of 86% on Record Revenue of approximately $46 million Boulder, CO, March 16, 2021- Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung di

Jan 8, 2021

Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue (unaudited) Record quarterly revenue driven by strength in COVID-19 testing and growth in lung diagnostic testing Boulder, CO

Biodesix Anticipates Strong Preliminary Fourth Quarter 2020 Revenue (unaudited) Record quarterly revenue driven by strength in COVID-19 testing and growth in lung diagnostic testing Boulder, CO, January 8, 2021 - Biodesix, Inc. a leading data-driven diagnostic solutions company

Jan 5, 2021

and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on

Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer Boulder, CO, January 4, 2021 - Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Ryan Siurek has joined the company as Chief Ac

Dec 10, 2020